Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
SENS enters the final month before its November 6 earnings report with a fresh analyst initiation pulling in one direction and a short-selling community that has spent six weeks quietly closing positions in the other.
The most notable positioning story is in options, where traders are expressing unusually strong bullish conviction. The put/call ratio has dropped to 0.14, well below its 20-day average of 0.23 and more than one standard deviation below the norm, the second-lowest reading of the past year against a 52-week low of 0.001. That ratio reflects a heavy tilt toward calls, not hedges. Shorts, meanwhile, have been pulling back steadily. Short interest as a percentage of the free float has fallen from around 13.4% in early September to 11.8% now, a 12% reduction over the month. The borrow market is relaxed: availability has eased to 235%, meaning there are more than two shares available to lend for every one already borrowed, a far cry from the near-zero availability hit at some point in the past year. Cost to borrow remains low at 0.69%, even after a 22% weekly tick higher. The short score of 66.9 is elevated in percentile terms but has drifted lower from a peak above 69 in late September, consistent with the gradual unwind.
The Street picture is more divided. Barclays initiated coverage this week with an Equal-Weight rating and a $10 price target, essentially a neutral verdict at current levels of $9.96. That sets a more cautious tone than the two bulls on the register: Mizuho holds an Outperform but cut its target to $18 from $20 in July, while HC Wainwright carries a Buy with a $14 target after trimming from $18.50 in May. Stifel sits at Hold with an $8 target. The mean target of $13.50 implies 35% upside from here, though the overall consensus is Hold. The bull case centres on a projected 90% year-over-year revenue increase driven by Eversense 365 patient conversions, with analysts forecasting $75.6 million in 2026 revenue and gross margins crossing 50% next year. Bears counter that first-half 2025 revenues were flat, losses per share are running ahead of estimates, and the competitive diabetes device market leaves little room for execution missteps. The short score ranks in the 7th percentile of the universe, meaning 93% of stocks are considered more short-friendly than SENS right now.
Institutional ownership tells a story of fresh conviction building fast. Sessa Capital IM filed a 13G disclosing a 9.9% stake in August 2026, making it the largest institutional holder with 4.4 million shares reported as of June 30, up by 2.7 million in the most recent period. BlackRock filed its own 13G in July showing 6.6% of the class. Avidity Partners and Sio Capital each reported new or substantially increased positions as of June 30, with Avidity's 1.6 million shares appearing to be an entirely new stake. None of these holders has filed a 13D, so no activist intent has been declared. As the disclosure note requires: these stakes are as last disclosed around the 5% threshold, and any holder dropping below that level may not file again. On the insider side, the recent Form 4 activity is largely grants, director compensation awards filed October 1 for small values. The one open-market purchase of note came from director Douglas Roeder in August, who bought roughly $125,000 worth of shares at $8.98, before the stock's most recent leg higher.
Earnings reactions for SENS have been dramatic. The last two prints produced one-day moves of 46% and 36% respectively, with five-day moves of 52% and 49%. Those figures are skewed by the Eversense 365 commercial ramp story, but they set a high bar for the November 6 release. The stock is up 3.4% over the past month at $9.96 despite a 0.9% dip on the week, and the peer group has broadly weakened: ICUI fell 2.3% on the week, MMSI dropped 3.3%, and ECOR shed nearly 9%.
With 30 days to the next print, the tension worth watching is whether the call-heavy options positioning and the retreat in short interest reflect genuine confidence in the revenue ramp, or simply a positioning reset ahead of what has historically been one of the most volatile earnings releases in the small-cap device space.
See the live data behind this article on ORTEX.
Open SENS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
